Biotechnology News and Research

RSS

Arcadia Biosciences' SONOVA 400 receives FDA approval as a dietary supplement ingredient

Arcadia Biosciences, Inc., an agricultural technology company focused on developing technologies and products that benefit the environment and human health, announced today that it has successfully completed the U.S. Food and Drug Administration (FDA) regulatory process for SONOVA™ 400.

8 Dec 2009

Anesiva receives notification letter from NASDAQ Stock Market

Anesiva, Inc. announced today that on December 2, 2009, Anesiva received a letter from The NASDAQ Stock Market ("Nasdaq") stating that Anesiva was required to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $5,000,000 during the last 30 consecutive business days and that therefore

8 Dec 2009

EPO grants patent for AbSorber's transplantation cross match-test

LinkMed’s subsidiary AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product. The European countries are highly prioritized markets for AbSorber and the patent approval is an important milestone in Absorbers intellectual property strategy.

8 Dec 2009

Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market.

8 Dec 2009

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec today announced that three-year follow up of the pivotal Phase III CLL8 trial showed Rituxan plus fludarabine and cyclophosphamide (FC) chemotherapy helped patients in the trial with previously untreated chronic lymphocytic leukemia (CLL) live longer than FC alone.

8 Dec 2009

Study: Besides nerves, skin has a unique sensory system

The human sensory experience is far more complex and nuanced than previously thought, according to a groundbreaking new study published in the December 15, 2009 issue of the journal Pain (http://www.painjournalonline.com/article/S0304-3959%2809%2900526-0/abstract).

8 Dec 2009

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).

8 Dec 2009

Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two abstracts describing preclinical studies with GMI-1070 have been selected for oral presentations at the 51st Annual American Society of Hematology (ASH) meeting being held December 5-8 in New Orleans.

8 Dec 2009

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

In addition to data released in late November, ChemoCentryx, Inc., announced today more data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease.

8 Dec 2009

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

Facet Biotech Corporation and Bristol-Myers Squibb Company announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented today at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.

8 Dec 2009

PolyMedix to present data on its heptagonist compounds

PolyMedix, Inc. (http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced that data will be presented on its heptagonist compounds at the annual meeting of the American Society of Hematology in New Orleans, Louisiana.

8 Dec 2009

Amgen announces results from first Phase 1/2 study of Nplate

Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Seattle Genetics, Inc. today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid® (lenalidomide) for multiple myeloma.

8 Dec 2009

Aston University researchers receive stimulus funds to study fundamental processes of human vision

A team of researchers led by Professor Mark Georgeson and Dr Timothy Meese at Aston University in Birmingham, UK have been awarded over £1 million pounds worth of funding from the BBSRC (Biotechnology and Biological Sciences Research Council) and the EPSRC (Engineering and Physical Sciences Research Council) to investigate some of the fundamental processes involved in human vision.

8 Dec 2009

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

La Jolla Pharmaceutical Company (“La Jolla”) today announced that it entered into a definitive merger agreement with Adamis Pharmaceuticals Corporation (“Adamis”) on December 4, 2009.

8 Dec 2009

Phase 1 study results of TRU-016 in patients with CLL announced

BioteTrubion Pharmaceuticals, Inc. and Facet ch Corp. today announced the presentation of positive data from a phase 1 study of TRU-016 in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) at the 2009 American Society of Hematology (ASH) Annual Meeting.

8 Dec 2009

Cell Biosciences expands its protein analysis business with Protein Forest acquisition

Cell Biosciences, Inc. today announced that it has acquired Protein Forest, Inc. of Lexington, Massachusetts, a leader in sample preparation technology for proteomic analysis and biomarker discovery.

7 Dec 2009

Millipore introduces new handheld, automated cell counter

Millipore Corporation, a leading provider of technologies, tools and services for the global life sciences industry, today introduced Scepter™, the industry’s first handheld, automated cell counter, at the American Society of Cell Biology Annual Meeting in San Diego.

7 Dec 2009

RCT licensee Dyax receives approval from the FDA for KALBITOR

RCT licensee Dyax Corp. has received approval from the U.S. Food and Drug Administration for KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.

7 Dec 2009

Biotechnology News and Research

Arcadia Biosciences' SONOVA 400 receives FDA approval as a dietary supplement ingredient

Anesiva receives notification letter from NASDAQ Stock Market

EPO grants patent for AbSorber's transplantation cross match-test

Specialty pharmaceutical market: Treatment patterns and product performance

Phase III CLL8 trial shows Rituxan plus FC chemotherapy improves patients with CLL

Study: Besides nerves, skin has a unique sensory system

Neovacs announces initiation of a Phase IIa clinical study of TNFα Kinoid immunotherapy

Two abstracts describing preclinical studies with GMI-1070 selected for oral presentations

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Potentially promising data from Phase I/II study of elotuzumab presented at ASH 2009

PolyMedix to present data on its heptagonist compounds

Amgen announces results from first Phase 1/2 study of Nplate

CAM314 randomized Phase 3 clinical trial results released

Data from two phase Ib clinical trials of dacetuzumab for DLBCL reported

Aston University researchers receive stimulus funds to study fundamental processes of human vision

La Jolla Pharmaceutical enters into definitive merger agreement with Adamis Pharmaceuticals

Phase 1 study results of TRU-016 in patients with CLL announced

Cell Biosciences expands its protein analysis business with Protein Forest acquisition

Millipore introduces new handheld, automated cell counter

RCT licensee Dyax receives approval from the FDA for KALBITOR

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News